Early weeks
Initiation
If your provider determines you're eligible, treatment typically begins at the lowest titration step. Many clients report appetite changes during this period; some experience GI adjustment.
A dual-action GLP-1 built around your labs.Tirzepatide
Tirzepatide is a dual GIP/GLP-1 receptor agonist. At Marek, every prescription is preceded by complete labs and reviewed by a partnered licensed medical provider, so eligibility, dose, and monitoring are determined by your data, not a template.
Up to 22.5%*
Body-weight reduction reported in clinical trials
80+
Biomarkers tested before medical provider prescription*
All 50
States licensed & HSA/FSA eligible
HSA/FSA eligible · No commitmentHSA/FSA eligible · No commitment
Weight · GLP-1
Marketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
Marketing purposes only. Actual medications, if prescribed, are dispensed by a licensed pharmacy.
Up to 22.5%*
Body-weight reduction reported in clinical trials
80+
Biomarkers tested before medical provider prescription*
All 50
States licensed & HSA/FSA eligible
Why Tirzepatide
What makes it different.
Dual GIP/GLP-1 mechanism
Up to 22.5% body weight loss
Weekly subcutaneous injection
Muscle-sparing coached protocol
What to expect
Your Tirzepatide timeline.
First few months
Provider-led titration
Your provider may adjust dosing based on tolerability, response, and follow-up labs. Your coach supports nutrition and body-composition tracking through any changes.
Mid-treatment
Follow-up labs
Repeat labs help your provider evaluate metabolic markers and confirm your protocol is working as intended. Adjustments are made when warranted.
Ongoing
Maintenance & off-ramp
Long-term planning is individualized. Some clients continue on a maintenance plan; others taper. Your coach helps build the lifestyle infrastructure that supports results.
How it works
From sign-up to treatment.From sign-up to your first dose.
Take the assessment
45-min intake with your dedicated health coach. A free health-score quiz is available before the paid intake.
Get your labs drawn
Complete lab panel ordered by your provider, drawn at any of 4,000 partnered lab locations nationwide. Results typically return within 14 days.
Provider reviews your results
A licensed medical provider reviews your labs and history to evaluate whether Tirzepatide is appropriate for you. Eligibility and any prescription are determined at the provider's discretion.
If eligible, treatment ships to your door
If your provider prescribes Tirzepatide, it ships from a licensed pharmacy. Your coach supports you through follow-up labs and ongoing monitoring.
The baseline panel.
Every Marek client receives this baseline panel before a provider review. Your provider may add additional biomarkers based on your health history, symptoms, and goals, pulling from 1,000+ available markers. See more biomarkers →
Hormone Profile
12 markers
Sex hormones
- Total TestosteroneLC/MS
- Free TestosteroneEquilibrium Dialysis
- Estradiol, Sensitive / UltrasensitiveLC/MS
- Sex Hormone Binding Globulin (SHBG)
- ProgesteroneLC/MSFemale panel
- Prolactin
- Luteinizing Hormone (LH)
- Follicle-Stimulating Hormone (FSH)
- hCG, Total, QuantitativeFemale panel, pre-menopause
Adrenals & neurosteroids
- Cortisol
- DHEA-S
Growth hormone / IGF-1
- Insulin-Like Growth Factor I (IGF-1)
Thyroid Status
3 markers
Thyroid hormones
- Thyroid Stimulating Hormone (TSH)
- Free T4
- Free T3
Heart Health
9 markers
Cardiovascular health
- Total Cholesterol
- HDL Cholesterol
- LDL Cholesterol
- LDL:HDL Ratio
- VLDL Cholesterol
- Triglycerides
- Apolipoprotein-B (ApoB)
- C-Reactive Protein, High Sensitivity (hsCRP)
- Lipoprotein(a) (Lp(a))
Metabolism
3 markers
Insulin sensitivity
- Blood Glucose
- Fasting Insulin
- HbA1c
Organ Function
26 markers
Liver & pancreas
- AST
- ALT
- Bilirubin, Total
- γ-Glutamyl Transferase (GGT)
Kidney function
- BUN
- Creatinine w/ eGFR
Comprehensive Metabolic Panel (CMP)
- Glucose
- Blood Urea Nitrogen (BUN)
- Creatinine
- eGFR
- BUN/Creatinine Ratio
- Sodium
- Potassium
- Chloride
- Carbon Dioxide, Total
- Calcium
- Protein, Total
- Albumin
- Globulin, Total
- Albumin/Globulin (A/G) Ratio
- Alkaline Phosphatase (ALP)
- AST
- ALT
Prostate health
- Prostate-Specific Antigen (PSA)Male panel
- Free PSAMale panel
- % Free PSAMale panel
Nutrient Status
31 markers
Vitamins & minerals
- Vitamin D, 25-OHD (25-Hydroxy)
- Magnesium, RBC
Iron status
- Iron
- Iron Saturation
- TIBC
- UIBC
- Ferritin
Complete Blood Count (CBC)
- White Blood Count (WBC)
- Red Blood Count (RBC)
- Hemoglobin (Hgb)
- Hematocrit (HCT)
- MCV
- MCH
- MCHC
- Red Cell Distribution Width (RDW)
- Platelets
- Neutrophils
- Neutrophils (Absolute)
- Lymphocytes
- Lymphocytes (Absolute)
- Neutrophil/Lymphocyte Ratio
- Monocytes
- Monocytes (Absolute)
- Eosinophils
- Eosinophils (Absolute)
- Basophils
- Basophils (Absolute)
- Immature Cells
- Immature Granulocytes
- Immature Granulocytes (Absolute)
- NRBC, w/ Reflex for Immature Cells
The science
How Tirzepatide works.
Tirzepatide is a first-in-class twincretin, a single peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor. This dual mechanism amplifies satiety signaling beyond what GLP-1 alone provides.
GIP receptor activation also engages adipose tissue directly, influencing fat storage and mobilization in a way GLP-1-only drugs do not. Combined with delayed gastric emptying and effects on pancreatic beta-cell function, this is the proposed mechanism by which Tirzepatide is associated with weight reduction and metabolic improvement in published trials.
In head-to-head studies (SURPASS-2), Tirzepatide showed greater A1c and body-weight reduction than semaglutide. Cardiovascular outcome trials are ongoing.
Considered for: obesity (BMI ≥30)Overweight (BMI ≥27) with comorbidityType 2 diabetesMetabolic syndrome
Eligibility, dosing, and outcomes vary. Any prescription is at the discretion of a partnered licensed medical provider based on your labs and medical history.
Clinical evidence
The research behind Tirzepatide.
SURMOUNT-1: Tirzepatide for obesity
New England Journal of Medicine (2022)
2,539 adults without diabetes. The highest study dose produced a mean body-weight reduction of approximately 20.9% at 72 weeks.
Read study →SURPASS-2: Tirzepatide vs. semaglutide
New England Journal of Medicine (2021)
1,879 patients with type 2 diabetes. Tirzepatide showed greater A1c reduction and weight loss than semaglutide 1mg across all study doses.
Read study →SURMOUNT-3: Durability after lifestyle phase
Nature Medicine (2023)
After a 12-week intensive lifestyle lead-in, adding Tirzepatide was associated with further weight reduction over 72 weeks, supporting its role as adjunctive therapy.
Read study →Safety profile
Monitoring & safety information.
Commonly reported side effects
- Nausea, especially during titration
- Reduced appetite / early satiety
- Constipation or diarrhea
- Mild fatigue (typically transient)
Less common but serious risks
- Pancreatitis
- Gallbladder disease
- Thyroid C-cell tumors (animal-model finding, FDA boxed warning)
- Hypoglycemia risk when combined with insulin or sulfonylureas
Generally not appropriate for
- Personal/family history of medullary thyroid cancer
- Multiple Endocrine Neoplasia syndrome type 2
- Pregnancy / breastfeeding
- History of pancreatitis
Typical monitoring
- HbA1c
- Lipid panel
- Thyroid function
- Kidney function
FAQ
Quick answers.
Eligibility, dose, and duration are determined by a partnered licensed medical provider based on your complete labs and medical history. A prescription is not guaranteed, your provider may recommend Tirzepatide, a different therapy, or a non-pharmacologic approach.
Tirzepatide activates both the GIP and GLP-1 receptors (a dual agonist); semaglutide acts on GLP-1 only. In a head-to-head trial (SURPASS-2), Tirzepatide showed greater A1c and body-weight reduction than semaglutide. Individual response varies and is not predictable in advance.
Commonly reported side effects include nausea, reduced appetite, and other GI symptoms during titration. Less common but serious risks include pancreatitis and gallbladder disease. Your provider reviews your history to evaluate whether Tirzepatide is appropriate, and your coach helps monitor symptoms throughout.
Pricing starts with a $299 intake assessment with your dedicated health coach. Lab pricing starts at $450. If your provider determines a prescription is appropriate, medication cost is separate and varies by dose. HSA/FSA eligible.
Some clients transition between GLP-1 medications under provider supervision. A switch is only made when the medical provider determines it is appropriate based on your labs, response, and history.
Some lean-mass loss is possible on any rapid weight-loss intervention. Marek's coached approach emphasizes protein-forward nutrition, resistance training guidance, and body-composition tracking, supporting lean-mass preservation rather than just scale weight.
Eligibility, dose, and duration are determined by a partnered licensed medical provider based on your complete labs and medical history. A prescription is not guaranteed, your provider may recommend Tirzepatide, a different therapy, or a non-pharmacologic approach.
Treatments are dependent on licensed clinical prescription. Client costs vary based on individual labs and panel in treatments and services.